Becton, Dickinson and Company and Danaher Corporation are leading players in Flow Cytometry Market

 Growth in the flow cytometry market is largely driven by the rising global incidence and prevalence of HIV/AIDS and cancer, growing adoption of flow cytometry techniques in research and academia, growing public-private initiatives in the fields of immunology and immuno-oncology research, technological advancements, increasing incorporation of AI platforms in flow cytometry workflows, and increasing advancements in flow cytometry software. However, the high cost of flow cytometry products is a major factor hampering the growth of the market.

The flow cytometry market is projected to reach USD 6.3 billion by 2026 from USD 4.3 billion in 2021, at a CAGR of 8.1%.

Download PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65374584

The prominent players in the global flow cytometry market include Becton, Dickinson and Company (US), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Luminex Corporation (US), Agilent Technologies, Inc. (US), Sony Group Corporation (Japan), Bio-Rad Laboratories, Inc. (US), Miltenyi Biotec GmbH (Germany), Enzo Biochem, Inc. (US), Sysmex Corporation (Japan), bioMérieux S.A. (France), Cytonome/ ST, LLC (US), Sartorius AG (Germany), Cytek Biosciences, Inc. (US), Union Biometrica, Inc. (US), Apogee Flow Systems Ltd. (UK), Stratedigm, Inc. (US), NanoCellect Biomedical, Inc. (US), On-chip Biotechnologies, Co., Ltd. (Japan), NEXCELOM BIOSCIENCE LLC (US), BennuBio Inc. (US), ORFLO Technologies (US), Bay Biosciences Co., Ltd. (Japan), BioLegend, Inc. (US), and CytoBuoy B.V (Netherlands). The analysis of market developments between 2018 and 2021 revealed that product launches and enhancements and acquisitions were adopted by market players to strengthen their product portfolios and maintain a competitive position in the flow cytometry market. Product launches and approvals were the most widely adopted growth strategies by market players.

BECTON, DICKINSON AND COMPANY (US)

BD is the leading player in the flow cytometry market. The company offers a significant number of products and consistently backs product launches with technological innovation. The company’s focus on innovative, user-friendly software solutions on flow cytometry has helped maintain its dominant position in the market.

Request Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=65374584

DANAHER CORPORATION (US)

Danaher Corporation is one of the leading players in the flow cytometry market. It operates in the nuclear medicine market through its Beckman Coulter subsidiary. This company primarily strategizes its growth through acquisitions, key collaborations, and product launches. Beckman Coulter significantly contributes to Danaher’s revenue through innovative research, advancement, expansion, and the launch of novel flow cytometry products. The company has a significant number of product launches and acquisitions in the flow cytometry market, especially in 2019 and 2020. This indicates the company’s focused strategy to emerge as a leader in this market in the near future.

Molecular Quality Controls Market: Increasing number of accredited clinical laboratories

 The growth of Molecular Quality Controls Market is primarily driven by factors such as the rising adoption of third-party quality controls, increasing number of accredited clinical laboratories, the rising demand for external quality assessment support, increasing government funding to support genomics projects, increasing demand for personalized medicines and declining costs of sequencing procedures and increasing prevalence of infectious diseases, cancer & genetic diseases.

The molecular quality controls market size is expected to grow from USD 164 million in 2021 to USD 226 million by 2026, at a CAGR of 6.7% during the forecast period. 

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82625523

Market Segmentation:

Based on product, the molecular quality control market is segmented into Independent Controls and Instrument Specific Controls. The Independent control segment accounted for the largest share of the market in 2020. The increasing number of accredited laboratories and mandates for the use of quality controls from regulatory bodies to ensure the accuracy of diagnostic test results are driving the growth of the molecular quality control products market.

Based on analyte type, the market is segmented into single-analyte controls and multi-analyte controls. Single-analyte controls dominated the molecular quality controls market in 2020 due to the significant use of singleplex assays in hospitals and the advantages associated with the use of single-analyte controls, such as simple analysis & interpretation and low risk of cross-reactivity.

Based on application, the molecular quality control market is segmented into infectious disease diagnostics, oncology testing, genetic testing, and other applications. The infectious disease diagnostics segment accounted for the largest share of the molecular quality controls market in 2020. The large share of this segment is attributed to the development of advanced assays for infectious diseases, a significant increase in the prevalence of infectious diseases, and the rising awareness about the effective use of molecular diagnostic technologies to control the occurrence and spread of infectious diseases.

The key end users of molecular quality controls studied in this report include diagnostic laboratories, hospitals, IVD Manufacturers and CROs Academic & Research Institutes, and other end users. The Diagnostic Laboratories segment accounted for the largest share of the market in 2020, increasing number of accredited diagnostic laboratories to provide growth opportunities in the coming years.

Regional Analysis:

The molecular quality control market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America was the largest regional market for molecular quality controls due to the developed healthcare system in the US and Canada, the presence of many leading molecular quality control product manufacturers in the region, and the easy accessibility to technologically advanced products in the region.

Request Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=82625523

Top Key Players:

The prominent players in the molecular quality controls market are F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific, Inc. (US), Randox Laboratories Ltd. (UK), LGC Limited (UK), Abbott Laboratories (US), Fortress Diagnostics (UK), SERO AS (Norway), Anchor Molecular (US), Ortho-Clinical Diagnostics, Inc. (US), Quidel Corporation (US), Sun Diagnostics, LLC (US), Seegene Inc. (South Korea), ZeptoMetrix, LLC (US), Qnostics (UK), Bio-Techne Corporation (US), Microbiologics, Inc. (US), Microbix Biosystems Inc. (Canada), SpeeDx Pty. Ltd. (Australia), Maine Molecular Quality Controls, Inc. (US), and Grifols, S.A. (Spain).

 

What are the major drivers in the laboratory proficiency testing market?

 The growth of laboratory proficiency testing market is primarily driven by factors such as it forms an essential precondition for operational excellence and accreditation in several industries. Also, the increasing number of laboratory accreditations, stringent safety and quality regulations for food and pharmaceutical products and the increasing focus on water testing are the other major factors supporting market growth. However, the requirement of high capital investments for accurate and sensitive testing is expected to restrain the growth of this market during the forecast period. The growth of the pharmaceutical proficiency testing market is driven by Stringent quality control in the production of pharmaceutical products, Growth of the pharmaceuticals market, Surge in the generics market, and Emerging biosimilars market while the major restraining factor is Cost and time-intensive drug manufacturing process.

The global laboratory proficiency testing market is projected to reach USD 1.4 billion by 2026 from USD 1.0 billion in 2021, at a CAGR of 6.4%. 

Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144227949

Market Segmentation:

Based on industry, the laboratory proficiency testing market is segmented into clinical diagnostics, food & animal feed, pharmaceuticals, microbiology, environmental, water, biologics, commercial beverages, cannabis/opioids, cosmetics, dietary supplements, and nutraceuticals. In 2020, the clinical diagnostics segment accounted for the largest share of the market. The large share of this segment is attributed to the development of complex diagnostic tests and the need for early diagnosis, which makes quality management with the use of proficiency testing an essential aspect of clinical diagnostics.

Based on technology, the global laboratory proficiency testing market has been segmented into spectrophotometry, chromatography, PCR, immunoassays, cell culture, and other technologies. The cell culture segment accounted for the largest share of the market in 2020. Growing awareness regarding the use of cell cultures in the production and testing of various clinical diagnostics samples, microbiology samples, and biopharmaceuticals is supporting the growth of this market.

Regional Analysis:

The laboratory proficiency testing market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share in the market. The large share of this region can be attributed to the mandatory adoption of laboratory proficiency testing to demonstrate operational excellence, increasing regulatory stringency regarding laboratory operations. The emerging markets across the Asia Pacific and Latin America are expected to grow at higher CAGRs during the forecast period. With significant growth in outsourcing services in the past few years, China and India have emerged as high-growth markets for laboratory proficiency testing. South Korea is another growing market in the APAC region. Other than these APAC countries, Latin American countries also show significant growth potential for the market.

Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=144227949

Top Key Players :-

The prominent players in the laboratory proficiency testing market are LGC Limited (UK), American Proficiency Institute (US), College of American Pathologists (US), Bio-Rad Laboratories (US), Randox Laboratories (UK), Merck (Germany), Fapas (Fera Science Ltd.) (UK), Waters Corporation (US), Weqas (UK), AOAC INTERNATIONAL (US), BIPEA (France), NSI Lab Solutions (US), Absolute Solutions (US), Trilogy Analytical Laboratories (US), Advanced Analytical Solutions (US), American Industrial Hygiene Association (US), Matrix Sciences (US), Aashvi Proficiency Testing & Analytical Services (India), and Global Proficiency (New Zealand).

 

Urinary Catheters Market: Growing prevalence of urinary incontinence

 The growing prevalence of urinary incontinence, an increasing number of surgical procedures across the globe, high incidence of prostate cancer, and the favorable reimbursement scenario are the major factors driving the growth of this market.

The global urinary catheters market size is projected to reach USD 2.6 billion by 2025 from USD 2.0 billion in 2020, at a CAGR of 5.5% during the forecast period.

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132934629

Market Segmentation :

Based on products, the global market is segmented into indwelling catheters, intermittent catheters, and external catheters. Indwelling catheters accounted for the largest share of the market in 2019. These catheters are also widely used in high-acuity patient units, with critical care and intensive care units registering the highest usage of indwelling catheters. Growth in this market is largely driven by the cost-efficiency and high availability of indwelling catheters in the market.

By catheter type, the global market is segmented into coated and uncoated catheters. Coated catheters accounted for the largest share of the market in 2019. This segment is also expected to register the highest CAGR during the forecast period. Growth in this market is mainly driven by the various advantages associated with coated catheters, such as easier, more comfortable insertion, low risk of catheter-associated urinary tract infection, reduced risk of urethral damage, and improved patient satisfaction.

Regional Analysis: -

The market is segmented into four major regions—North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America was the largest regional market for urinary catheters in 2019. The large share of North America in this market can be attributed to the favorable reimbursement scenario and the rising volume of surgeries in the region. However, the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. The high growth in this market can be attributed to the growing healthcare spending in emerging Asian countries, rising prevalence of urinary incontinence, and the large target patient population in the region.

Request for Sample pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=132934629

Top Key Players:-

The global urinary catheters market is highly consolidated. The prominent players operating in this market include B. Braun Melsungen AG (Germany), Boston Scientific Corporation (US), Coloplast Ltd. (Denmark), ConvaTec Inc. (UK), Becton, Dickinson and Company (US), Cardinal Health (US), Teleflex Incorporated (US), Wellspect HealthCare (US), and Cook Medical (US). Other players include Asid Bonz GmbH (Germany), Degania Silicone Ltd. (Israel), Bactiguard (Sweden), Medical Technologies of Georgia (US), ROCAMED (Monaco), Well Lead Medical Co., Ltd. (China), Go Medical Industries Pty Ltd. (Australia), Cure Medical, LLC, Amsino International, Inc. (US), Urocare Products, Inc. (US), J and M Urinary Catheters LLC. (US), CompactCath (US), Hunter Urology (England), MANFRED SAUER GMBH (Germany), and Ribbel International Limited (India).

 

Animal Growth Promoters and Performance Enhancers Market: Rise in the global demand for naturally produced growth promoters

 Animal health products, including growth promoters and performance enhancers, are types of drugs and chemicals used for animal growth. These enhancers help to digest food more effectively and enable animals to grow faster, which, in turn, help to improve productivity. Growth in the animal growth promoters and performance enhancers market is majorly driven by the rising demand for animal consumption and consumption of livestock-based products, rising global demand for naturally produced growth promoters, and rising animal epidemics and climate change. However, a ban on antibiotics in different nations and stringent regulations restricting the use of antibiotics and hormones for growth promotion in animals are expected to restrain the growth of the animal growth promoters and performance enhancers market during the forecast period.

The global Animal growth promoters and performance enhancers market is projected to reach USD 21.4 billion by 2026 from USD 16.2 billion in 2021, at a CAGR of 5.7%.

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137134167

Market Segmentation: -

The non-antibiotic growth promoters and performance enhancers segment accounted for the largest share of the animal growth promoters and performance enhancers market in 2020. The large share of this segment can be attributed to the economic benefits of these products, the wide range of substances with applications in different production animals, environmental sustainability, and the increased number of regulations on antibiotics and hormones.

The poultry segment accounted for the largest share of the global animal growth promoters and performance enhancers market. The large market share of this segment can be attributed to the increasing demand for poultry meat and eggs, rising novel diet approaches, and increasing antibiotic phase-outs resulting in the development of alternatives.

Regional Analysis: -

Asia Pacific region accounted for the largest market share, followed by North America with a share in 2020. The large share of the Asia Pacific region can be attributed to the strong animal products industry in this region, huge population generating greater domestic meat demand, comparatively relaxed regulatory scenario, and government efforts to encourage animal producers.

Request Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=137134167

Top Key Players: -

Prominent players in the Animal Growth Promoters and Performance Enhancers Market include are Cargill, Incorporated (US), Royal DSM N.V. (Netherlands), Elanco Animal Health Incorporated (US), Boehringer Ingelheim Group (Germany), Merck & Co., Inc (US), Alltech Corporation (US), Archer-Daniels-Midland Company (ADM) (US), Vetoquinol S.A. (France), Bupo Animal Health Pty Ltd. (South Africa) and Novus International, Inc. (US).

Endoscopic Retrograde Cholangiopancreatography Market: The growing healthcare sector in emerging economies

 The growth of Endoscopic Retrograde Cholangiopancreatography Market is majorly attributed to factors such as the rising incidence of cancer, increasing investments by governments and healthcare organizations to improve endoscopy research, growing focus on investments by hospitals for advanced endoscopy instruments, and the increasing preference for minimally invasive surgeries. On the other hand, the high costs of endoscopic retrograde cholangiopancreatography devices, the development of other procedures like EUS and MRCP, and the shortage of trained physicians and endoscopists are factors expected to restrain the market growth to a certain extent.

The global endoscopic retrograde cholangiopancreatography market is projected to reach USD 2.0 billion by 2026 from USD 1.3 billion in 2021, at a CAGR of 9.6% during the forecast period.

Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=170242954

Market Segmentation

Based on products, the endoscopic retrograde cholangiopancreatography market has been segmented into endoscopes, endotherapy devices, visualization systems, energy devices, and others. The factors attributing to the large revenue of the endotherapy devices segment include the growing preference for minimally invasive surgeries and the increasing prevalence of gastrointestinal conditions.

In the endotherapy devices segment, sphincterotomes accounted for the largest market share during the forecast period. This can be attributed to the increasing incidence of pancreatic duct and bile duct stones and the growing geriatric population leading to an increase in biliary disorders.

Regional Analysis:

North America accounted for the largest share of the ERCP market in 2020. The increasing prevalence of cancer, high investments by hospitals to purchase new ERCP equipment, and a strong focus on research activities to improve endoscopy techniques are the major factor contributing to this.

Request Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=170242954

Top Key Players:

The major players in the global endoscopic retrograde cholangiopancreatography market include Olympus Corporation (Japan), CONMED Corporation (US), Fujifilm Holdings Corporation (Japan), HOYA Corporation (Japan), KARL STORZ SE & Co. KG (Germany), Ambu A/S (Denmark), Boston Scientific Corporation (US), Johnson & Johnson (US), Medtronic, PLC (Ireland), Cook Medical (US), and B. Braun Melsungen AG (Germany).

Benign Prostatic Hyperplasia Treatment Market: Increasing prevalence of benign prostatic hyperplasia

 The growth of Benign Prostatic Hyperplasia Treatment Market is driven by the increasing prevalence of benign prostatic hyperplasia, the rising preference for minimally invasive surgeries, increasing obesity rate, and investments, funds, and grants for research in the field of BPH treatment.

The Benign prostatic hyperplasia treatment market is projected to reach USD 14.1 billion by 2026 from USD 10.8 billion in 2021, at a CAGR of 5.3% from 2021 to 2026. 

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198000374

Market Segmentation :-

Based on the type, the BPH treatment market is segmented into drug treatment and surgical treatment. Drug treatment is the largest and the fastest-growing segment in this market. This can primarily be attributed to the use of medications as the first line of treatment among men with mild to moderate symptoms of BPH.

Based on the end user, the market is segmented into home healthcare and hospitals & clinics. In 2019, home healthcare accounted for the largest share of this market, as most patients are prescribed medications over surgery. Patients are also advised to continue taking medications for a few weeks post-surgery and may even require catheters for a few days. As a result, the emphasis in his market is skewed toward home healthcare over hospital care.

Regional Analysis:

On the basis of region, the benign prostatic hyperplasia treatment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2019, North America commanded the largest share of the benign prostatic hyperplasia treatment market. The large share of this market segment can be attributed to the rising geriatric and obese population and the availability of research funding are the major factors driving the market growth. Initiatives by key players are also expected to contribute to the market.

Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=198000374

Top Key Players: -

The major players operating in this market are Boston Scientific Corporation (US), Coloplast Group (Denmark), Teleflex Incorporated (US), Olympus Corporation (Japan), GlaxoSmithKline PLC (UK), Eli Lilly (US), Pfizer, Inc. (US), Abbott (US), Asahi Kasei Corporation (Japan), Merck & Co., Inc. (US), Astellas Pharma Inc. (Japan), Allergan plc (Ireland), Alembic (India), IPG Photonics Corporation (US), Richard Wolf GmbH (Germany), Unilab, Inc. (Philippines), Pharex Health Corporation (Philippines), Biolitec AG (Austria), Urologix, LLC (US), Advin Health Care (India), Medifocus, Inc. (Canada), Asclepion Laser Technologies GmbH (Germany), Pnn Medical A/S (Denmark), Surgical Lasers Inc. (Canada). Quanta Systems (Italy), Allium Ltd. (Israel), Lumenis Ltd. (Israel), KARL STORZ SE & Co. KG (Germany), and SRS Medical (US).

 

Intuitive Surgical, Stryker Corporation and Medtronic are the Prominent Players in the Surgical Robots Market

 Surgical robots enable surgeons to carry out complex surgical procedures with greater precision. They are primarily used in gynecological, urological, orthopedic, general, neurosurgeries, and other minimally invasive surgeries. Growth in this market is primarily driven by the advantages of robotic-assisted surgery, technological advancements in surgical robots, the increasing adoption of surgical robots, and the increase in funding for medical robot research. On the other hand, the high cost of robotic systems is a key factor limiting market growth in the coming years.

The global Surgical robots market is projected to reach USD 14.4 billion by 2026 from USD 6.4 billion in 2021, at a CAGR of 17.6% during the forecast period.

 

Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=256618532

Some of the prominent players operating in the Surgical robots  market are Intuitive Surgical (US), Stryker Corporation (US), Medtronic (Ireland), Smith & Nephew (UK), Zimmer Biomet (US), Asensus Surgical (Transenterix) (US), Corindus Vascular Robotics (US), Renishaw (UK), Auris Health (US), Medrobotics Corporation (US), Think Surgical (US), Verb Surgical (US), OMNIlife Science (US), CMR  Surgical (US), Preceyes BV (Netherlands), China National Scientific Instruments And Materials Corporation (CSIMC) (China), Microsure (Netherlands), Titan Medical (Canada), avateramedical Gmbh (Germany) and Medicaroid Corporation (Japan).

Top Surgical Robots Market Player

Intuitive Surgical was the largest player in the surgical robots market. Being a pioneer in surgical robots, Intuitive Surgical successfully established a brand of its own. The FDA approvals of the company’s key products, such as the da Vinci X Surgical System and the launch of its Single-port Platform in 2018, have further augmented the company’s position in the surgical robots market. Continuous advancements in its robotic systems have also helped the firm maintain a strong leading position. More than 8.5 million minimally invasive procedures have been performed worldwide through 2020 using the da Vinci surgical system.

Stryker Corporation was the second-leading player in the surgical robots market. Stryker is also the leader in the orthopedic robotic systems market. The acquisition of Mako Surgical Corporation in 2013 enabled the company to enter the surgical robots market. The company’s surgical robots portfolio was further strengthened by introducing the Mako Total Hip and Mako Partial Knee. In 2017, Stryker received FDA clearance to use the Mako robotic surgery system for total hip replacement applications, which further helped strengthen its market position. Stryker also has a significant installation base of its systems across the world. As of October 2020, 860 robots were installed, of which 700 were placed in the US. The company reported strong growth in 2019, as the units sold increased by 28%, from 165 units in 2018 to 212 units sold in 2019. Also, the number of procedures conducted by Mako robots increased to more than 120,000 in 2020.

Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=256618532

Medtronic was the third-largest player in the surgical robots market. The acquisition of Mazor Robotics in December 2018 enabled the firm to enter the medical robots market. In 2019, Medtronic’s surgical robots portfolio was further strengthened by the commercial launch of the Mazor X Stealth Edition for robotic-assisted spine surgeries in the US. Medtronic also unveiled its new robot-assisted surgery platform, the Hugo RAS system, which is expected to give Intuitive Surgical’s market-dominating da Vinci robot tough competition. Hugo RAS has a pedestal-based modular system, with components upgraded individually and a surgeon console open to the operating room.